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AbstrACt
Introduction Previous research from the Blood Pressure 
Lowering Treatment Trialists’ Collaboration (BPLTTC) and 
others has shown that pharmacological blood pressure 
(BP)- lowering substantially reduces the risk of major 
cardiovascular events, including ischaemic heart disease, 
heart failure and stroke. In this new phase, the aim is to 
conduct individual patient-level data (IPD) meta-analyses 
involving eligible BP-lowering randomised controlled trials 
(RCTs) to address uncertainties relating to efficacy and 
safety of BP-lowering treatment.
Methods and analysis RCTs investigating the effect 
of pharmacological BP-lowering, with a minimum of 
1000 patient-years of follow-up in each trial arm, are 
eligible. Our systematic review identified 100 potentially 
eligible trials. We requested their investigators/sponsors 
to contribute baseline, follow-up and outcomes data. 
As of June 2018, the collaboration has obtained data 
from 49 trials (n=315 046 participants), with additional 
data currently in the process of being transferred from 
four RCTs (n=34 642 participants). In addition, data 
harmonisation has commenced. Scientific activities of 
the collaboration are overseen by the Steering Committee 
with input from all collaborators. Detailed protocols for 
individual meta-analyses will be developed and registered 
on public platforms.
Ethics and dissemination Ethics approval has been 
obtained for this new and extended phase of the BPLTTC, 
the largest collaboration of de-identified IPD from RCTs. 
It offers an efficient and ethical manner of re-purposing 
existing data to answer clinically important questions 
relating to BP treatment as well as methodological 
questions relating to IPD meta-analyses. Among the 
immediate impacts will include reliable quantification of 
effects of treatment modifiers, such as baseline BP, age 
and prior disease, on both vascular and non-vascular 
outcomes. Analyses will further assess the impact of BP-
lowering on important, but less well understood, outcomes, 
strengths and limitations of this study
 ► This protocol aims to conduct individual patient-lev-
el data (IPD) of blood pressure (BP)-lowering ran-
domised clinical trials (RCT) to address stratified 
efficacy of BP-lowering treatment according to 
various patient characteristics, examine the impact 
of BP-lowering treatment on less-studied vascular 
outcomes, and identify unintended consequences of 
such treatment.
 ► With data from 49 RCTs (>300 000 participants) 
already shared in the collaboration, it will be the 
largest IPD meta-analysis of any randomised trials, 
allowing sufficient statistical power to address a 
number of important clinical questions a single BP-
lowering randomised trial is unlikely to be able to 
answer reliably on its own.
 ► Findings of meta-analyses from this resource are 
likely to provide reliable evidence to inform clinical 
guidelines and public health policy development.
 ► Data from some RCTs are not accessible because 
some investigators, particularly of older trials, could 
not be traced or sponsors/funders of the trials are 
unwilling to share data.
 ► Not all RCTs would have collected the same clinical 
information so missing data are inevitable for some 
studies; appropriate methods to address these is-
sues would have to be utilised.
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such as new-onset diabetes and renal disease. Findings will be published 
in peer-reviewed medical journals on behalf of the collaboration.
IntroduCtIon
Elevated blood pressure (BP) is a major risk factor for 
cardiovascular death and disability worldwide, and its 
burden has been increasing. In 2016, elevated BP above 
the minimum risk exposure threshold of 110 mm Hg 
systolic was responsible for >10 million deaths and 7% of 
the world’s total disability-adjusted life years .1 
Several randomised trials and their meta-analyses have 
shown that pharmacological BP-lowering is an effective 
and affordable strategy for management of cardiovascular 
risk. Despite this, treatment and control rates among 
those who have been classified to have ‘hypertension’ (BP 
>140/90 mm Hg) remain low in both high-income and 
low-income countries.2 This gap between evidence and 
practice is likely to be at least in part due to remaining 
uncertainties about the efficacy and safety of BP-lowering.3 
For instance, there is no expert consensus on the appro-
priate BP threshold for treatment initiation and whether 
this should differ by age or disease status (eg, diabetes or 
coronary heart disease (CHD)). Also, little is known on 
the effects of BP-lowering on safety outcomes (eg, cancer, 
falls and fractures, and acute kidney injury), non-vascular 
outcomes (eg, new-onset diabetes, dementia) or less 
commonly reported vascular outcomes (eg, atrial fibrilla-
tion, peripheral arterial disease, aortic aneurysms, pulmo-
nary embolism and stroke subtype).
These existing uncertainties have major consequences 
for patient management and outcomes. On the one 
hand, lack of reliable estimates for the efficacy of BP 
lowering on less commonly reported vascular outcomes, 
some of which have a clear association with BP in obser-
vational studies,4–7 may result in an underestimation of 
the overall impact of BP-lowering in the general patient 
population. On the other hand, uncertainty about the 
safety of BP-lowering could potentially expose specific 
patient groups to avoidable harms because of overuse 
or underuse of BP-lowering treatment. To address these 
uncertainties, more evidence from randomised trials 
are needed. However, because single randomised trials 
are often not large enough for detailed investigation of 
the safety and efficacy of BP-lowering and its variation 
by a class of medication or important patient features, 
pooling information from several trials remains the most 
efficient and often the only viable option for addressing 
these remaining uncertainties.
In 1995, principal investigators of major ongoing 
clinical trials of BP-lowering drugs conceived and initi-
ated the Blood Pressure Lowering Treatment Trialists’ 
Collaboration (BPLTTC) to investigate the effect of 
BP-lowering on major cardiovascular events and all-cause 
mortality through a series of individual patient-level data 
(IPD) meta-analyses.8 Since its inception, the BPLTTC 
has successfully completed several studies which have 
provided reliable evidence for the benefits of BP-lowering 
for prevention of major cardiovascular outcomes (CHD, 
heart failure and stroke) and have demonstrated that 
major classes of antihypertensives have similar beneficial 
effects on major vascular outcomes.9–13 However, with its 
limited size and original focus on major cardiovascular 
outcomes only, the BPLTTC has been unable to address 
important contemporary questions about the stratified 
(ie, subgroup-specific) effects of BP-lowering and its 
safety.
objECtIvEs
In 2014, existing BPLTTC investigators were approached 
and asked to extend the scope of the collaboration with 
the provision of information on all available and acces-
sible baseline, follow-up and outcomes data. In addition, 
investigators from several other large-scale trials who had 
not participated in BPLTTC or had provided summary 
data only were invited to join the collaboration with 
the provision of IPD. The key objectives for this extended 
phase of BPLTTC were specified as follows:
1. To assess the stratified efficacy of BP-lowering on ma-
jor vascular events (CHD, stroke and heart failure) and 
all-cause mortality by baseline BP levels, sex, age, dis-
ease status (including multimorbidity) and risk of CVD 
at baseline.
2. To assess the overall and stratified safety of BP-lower-
ing by examining its effect on unintended outcomes, 
including total serious adverse events, acute renal fail-
ure, new-onset diabetes, fractures and cancer overall, 
and by drug classes and baseline BP levels.
3. To assess the extended efficacy of BP-lowering on 
other important ‘vascular’ outcomes, including atrial 
fibrillation and dementia.
MEthods And AnAlysIs
Inclusion and exclusion criteria
For this extended phase of the collaboration, the orig-
inal trial eligibility criteria were modified, chiefly to 
enable inclusion of additional large-scale trials that were 
reported before the inception of the BPLTTC in 1995. We 
will only include randomised clinical trials to minimise 
the impact of bias and confounding. For clinical trials to 
be eligible for inclusion in BPLTTC, one of the following 
criteria must be met:
 ► Randomisation of patients between a BP-lowering 
agent and a placebo arm (or other inactive control 
condition).
 ► Randomisation of patients between various BP-low-
ering intensities.
 ► Randomisation of patients between various antihyper-
tensive drugs.
Additionally, a minimum of 1000 patient-years of 
follow-up in each randomly allocated trial arm is required. 
There is no restriction on publication date, setting or 
drugs investigated. However, the following types of trial 
will be excluded:
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 ► Trials exclusively conducted in patients with heart 
failure or short-term interventions in patients with 
acute myocardial infarction or other acute settings.
 ► Trials with non-pharmacological interventions of 
BP-lowering without a drug comparison arm.
 ► Trials without a clearly defined randomisation process.
Identification of trials
We conducted a systematic review to identify trials for 
possible inclusion in the IPD meta-analysis. The search 
was restricted to clinical trials, controlled clinical trials, 
randomised controlled trials or meta-analyses and no 
language restrictions were applied. We searched elec-
tronic bibliographic databases, including PubMed/
Medline (NCBI, Bethesda, MD, USA), The Cochrane 
Central Register of Controlled Trials (The Cochrane 
Collaboration, London, UK) and the  ClinicalTrials. gov 
website covering the periods between 1 January 1966 
and 1 June 2018. Reference lists of eligible studies, 
related meta-analyses, clinical trial registries and BPLTTC 
collected in previous projects14 were hand-searched to 
identify further relevant studies. This systematic review 
protocol, including details of the methods and search 
strategy, was registered with PROSPERO ( www. crd. 
york. ac. uk/ prospero/) (CRD42018099283) before the 
review was conducted. The online supplementary table 
1 shows the Medline search strategy. For this protocol, 
the Preferred Reporting Items for Systematic review and 
Meta-Analysis Protocols (PRISMA-P) checklist is shown in 
the online supplementary table 2.
We used reference management software (Endnote) to 
store identified records from different sources. Duplicate 
records from various sources were collapsed into a single 
entry. Two investigators (DC and MN) conducted inde-
pendent searches and screened the title and abstracts 
of publications for meeting eligibility criteria. The full 
manuscript was then requested and assessed for eligi-
bility. Disagreements were resolved by discussion, with 
the involvement of a third investigator (KR) where 
necessary.
Because the purpose of this systematic review was to 
identify potential trials for inclusion in an IPD meta-anal-
ysis, we mainly extracted information about the investi-
gators and/or contact details to allow us to invite them 
to participate by contributing data. When conducting the 
meta-analysis of RCTs for which we have obtained data at 
individual patient-level, we will report quality assessment 
of these RCTs based on randomisation procedures, treat-
ment allocations according to assignment, and outcomes 
collected and compared across comparison groups; 
concealment and blinding methods; and risk of bias both 
at study and outcome levels using the Cochrane Risk of 
Bias Tool. We will use the quality of RCTs as part of sensi-
tivity analysis when conducting the IPD meta-analysis.
Figure 1 summarises the trial search as of June 2018, 
indicating that a total of 100 trials with 595 514 randomised 
participants were identified which potentially met the 
BPLTTC eligibility criteria (online supplementary table 
3). This literature search will be continuously updated, 
and investigators of newly reported and eligible trials will 
be invited to join the collaboration.
dAtA CollECtIon
All existing BPLTT collaborators and investigators of all 
newly identified trials were contacted and asked whether 
they would be willing to provide IPD (variables are listed 
in the online supplementary table 4). As of June 2018, the 
collaboration had acquired data from 49 trials comprising 
315 046 participants. Investigators or sponsors of several 
other trials have agreed to share data. Data from another 
four major trials with 34 642 participants are currently at 
the transfer stage. For the remaining trials, data are still 
being sought. Many of these trials have been published 
many years ago and identification of the data guardian or 
an electronic database of the trial has proven challenging.
In parallel to requesting further data, the process 
of data harmonisation has commenced. This includes 
a creation of a database with all information obtained 
from investigators, using the data dictionary provided. 
Initial data verification will include checking of the indi-
vidual patient data with respect to a number of partici-
pants, baseline characteristics, and types of follow-up and 
outcome data available. Next, prepared data are to be 
checked for consistency (eg, plausible ranges, randomi-
sation sequence and so on) and completeness. In case of 
any inconsistencies or missing information, the investiga-
tors will be contacted for verification.
Figure 1 Literature search and trial selection flowchart. 
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Governance and data management policies
Figure 2 provides an overview of the roles and responsi-
bilities of the BPLTTC collaborative group. The BPLTTC 
Director, supported by a core analytic and management 
group, at the University of Oxford coordinates all activ-
ities among internal collaborators and external stake-
holders. This central team will periodically update the 
literature review, acquire new data, develop proposals 
and protocols, seek approvals and funding, and manage 
publications and communication. Scientific activities of 
the BPLTTC core group are overseen by the Steering 
Committee with input from all BPLTT collaborators.
The aforementioned three main objectives of the 
extended phase of BPLTTC have all been approved by 
the Steering Committee and collaborators. For each of 
these objectives, at least one study protocol will be devel-
oped. Collaborators or external researchers may suggest 
additional research proposals to the BPLTTC core group. 
Such proposals shall be checked for feasibility and overlap 
with any existing proposals. If appropriate, they will be 
shared with the Steering Committee for scientific review. 
After approval, proposing researchers will be able to join 
a working group, including other interested members of 
the Collaboration. This working group will work with the 
BPLTTC core group and Steering Committee to write 
the research protocol, conduct and interpret the results, 
draft the manuscript and publish the final report.
Once agreement on a structured protocol is reached 
by the working group, the study will be registered with 
PROSPERO and the protocol will be posted on a pass-
word protected website at www. bplttc. org. Additionally, 
collaborators will be able to use this website to stay 
informed about the progress of various projects.
Trial data from investigators and sponsors are typically 
transferred by using a secure file transmission system, 
such as Oxford’s Oxfile system. Before sending a data file, 
the data will be compressed using a standard compression 
system and then encrypted. All data transfer processes 
will be overseen by the BPLTTC core group in compli-
ance with the data exchange and sharing agreement with 
the data provider. All trial data will be considered confi-
dential and will not be provided to any third party without 
written permission of the owner of the data. Data will be 
stored on site at The George Institute at the University 
of Oxford, with strict confidentiality and comprehensive 
data security. All analyses will be carried out by the core 
analytic team, according to research priorities and avail-
ability of resources.
Patient and public involvement
This protocol describes plans for collaborative research 
investigations involving secondary analyses of existing 
clinical trials data. There was neither any involvement by 
patients in conceptualising the study nor in the develop-
ment of the protocol.
statistical analysis
Prior to commencing any analysis, a feasibility assess-
ment and power calculation will be carried out on the 
blinded dataset. For approved proposals, a protocol will 
be written which will entail a detailed statistical analysis 
plan. Although specific proposals may require different 
Figure 2 Overview of collaboration governance. BPLTT, Blood Pressure-Lowering Treatment Trialists’ Collaboration 
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statistical methods, in principle, we intend to use a 
one-step approach by simultaneously analysing observa-
tions from all trials (while accounting for clustering of 
observations within studies).15 16 This approach is more 
suitable than a two-step approach when non-linear effects 
or multiple covariates and their interaction are to be 
assessed, which our stratified analyses aim to do.17 For 
some analyses, it might be important to supplement the 
available IPD with aggregate data for those studies where 
IPD are not available, using a combined one-step and 
two-step approaches. Aggregate data will be obtained by 
sending our computer codes to the Investigators of such 
studies, so as to extract their results (eg, HRs), rather 
than their data.
We will use fixed effects methods to pool trial-specific 
data. For time-to-event data, clustered Cox proportion-
al-hazard models will be used and HRs with 95% or 99% 
CIs will be reported. For binary outcomes, risk ratios and 
95% CI will be estimated using log-binomial mixed-ef-
fects models (or ORs from logistic models, if necessary). 
Effects on continuous outcomes (eg, renal function) will 
be quantified by mean differences and 95% CI and will be 
estimated using linear mixed effects models.
Using a two-step approach, key results will be presented 
using Forest plots, and Cochran’s Q test and I2 statistic 
will be used to quantify the degree of heterogeneity 
between studies. Meta-regression will be used if consid-
erable residual heterogeneity remains after controlling 
for all possible variables and recognised effect modifiers, 
with P-value adjusted for false positive findings based on 
Monte Carlo simulation.
Where appropriate, analyses will also be stratified by 
class of medication, patient population and baseline BP 
to allow for heterogeneity among different patient popu-
lations and types of medication to be determined. In 
addition, a dose-effect (dose-response) regression model 
will be applied to assess any potential dose-effect associa-
tion for each medication dosage and represent efficacy 
and probable risk of side effects (point-to-point associa-
tion) both at individual and trial levels (aggregate data). 
Also, we will use fractional polynomials and cubic splines 
to smoothen the dose–response relationship and address 
any violated linearity assumption.18 For analysing drug 
class-specific effects, we will consider using IPD network 
meta-analysis.19
Most trials included in BPLTTC have a double-blind 
design where the use of routine unadjudicated outcomes 
is unlikely to result in biased estimates (provided a suffi-
cient number of events can be gathered) because any 
under- reporting or over-reporting would affect both arms 
of the trial equally.20 21 However, due to the different data 
formats of contributing trials and potentially different 
types of data provided, additional methodological work 
might be needed to enhance the quality and power of 
the data. This might be particularly relevant when a 
large proportion of data on important covariates, effect 
modifiers or outcomes is missing. Simply ignoring the 
missing data, or implementing a complete case analysis, is 
typically inappropriate, as it could result in biased results. 
We will, therefore, conduct methodological studies that 
will compare existing and novel methods for imputation 
of non-commensurate measurements between trials, 
correction of measurement errors or harmonisation of 
differing definitions among trials.22–25
In general, reporting of the findings will follow the 
PRISMA-IPD guidance26 and where appropriate, we will 
use Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) ( www. gradeworking-
group. org) when assessing the certainty of evidence.
Ethics and dissemination
As we do not have access to patient identifiable informa-
tion, our procedures are fully compliant with the Data 
Protection Act 1998 and consistent with the principles of 
the General Data Protection Regulation. The University 
of Oxford’s research contracts team is well aware of legal 
requirements for data sharing and storage and all our 
procedures are fully compliant with these requirements. 
These requirements are described in detail in Oxford’s 
research governance (https:// researchsupport. admin. 
ox. ac. uk/ governance/ integrity) and policies on research 
data handling and management (http:// researchdata. ox. 
ac. uk/). We have already obtained ethics review from the 
Oxford Central Ethics University Research Committee 
(OxTREC Reference: 545–14) and agreed to communi-
cate any major amendments to the protocol for this third 
cycle of BPLTTC with the Ethics Committee for further 
approval before analyses begin.
The knowledge of the degree of efficacy and safety of 
BP-lowering and its variation by a class of medication and 
among subgroups of patients will help to refine treatment 
recommendations. The presence of clinically meaningful 
differences in the efficacy of different classes of BP medica-
tion, either overall, or within certain patient groups will have 
considerable implications for stratified patient manage-
ment and clinical decision-making. BPLTTC is the largest 
international hypertension collaboration and is unique in 
its ability to pool and analyse IPD from a large number of 
trials to answer these clinically relevant questions.
We will publish our findings in peer-reviewed medical 
journals. Further, we will share and present our findings 
at various scientific meetings and through the Collabo-
ration’s networks and memberships across professional 
societies. The George Institute for Global Health has 
communication and dissemination practices in place to 
ensure that research it produces and policies it contrib-
utes to are regularly transmitted through its various insti-
tutes and units in Australia, India, China, UK and the 
USA and to its partner organisations globally.
Details about data curation and deposition are described 
under the section on ‘Governance and data management 
policies’. No data will be provided to any third party without 
written permission from the trial data provider or custo-
dian. As previously mentioned, the BPLTTC is governed 
by the University of Oxford’s policies on research integrity 
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and codes of practice and follow the university policy on the 
management of research data and records.
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